348 related articles for article (PubMed ID: 32758395)
1. Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis.
McComb M; Krikheli M; Uher T; Browne RW; Srpova B; Oechtering J; Maceski AM; Tyblova M; Jakimovski D; Ramasamy DP; Bergsland N; Krasensky J; Noskova L; Fialova L; Weinstock-Guttman B; Havrdova EK; Vaneckova M; Zivadinov R; Horakova D; Kuhle J; Ramanathan M
J Clin Lipidol; 2020; 14(5):675-684.e2. PubMed ID: 32758395
[TBL] [Abstract][Full Text] [Related]
2. Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis.
Uher T; McComb M; Galkin S; Srpova B; Oechtering J; Barro C; Tyblova M; Bergsland N; Krasensky J; Dwyer M; Havrdova EK; Posova H; Vaneckova M; Zivadinov R; Horakova D; Kuhle J; Ramanathan M
Mult Scler; 2021 Feb; 27(2):220-231. PubMed ID: 32255388
[TBL] [Abstract][Full Text] [Related]
3. Apolipoproteins AI and E are associated with neuroaxonal injury to gray matter in multiple sclerosis.
McComb M; Parambi R; Browne RW; Bodziak ML; Jakimovski D; Bergsland N; Maceski A; Weinstock-Guttman B; Kuhle J; Zivadinov R; Ramanathan M
Mult Scler Relat Disord; 2020 Oct; 45():102389. PubMed ID: 32683305
[TBL] [Abstract][Full Text] [Related]
4. Serum neurofilament light chain in pediatric MS and other acquired demyelinating syndromes.
Wong YYM; Bruijstens AL; Barro C; Michalak Z; Melief MJ; Wierenga AF; van Pelt ED; Neuteboom RF; Kuhle J; Hintzen RQ
Neurology; 2019 Sep; 93(10):e968-e974. PubMed ID: 31383792
[TBL] [Abstract][Full Text] [Related]
5. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
Disanto G; Barro C; Benkert P; Naegelin Y; Schädelin S; Giardiello A; Zecca C; Blennow K; Zetterberg H; Leppert D; Kappos L; Gobbi C; Kuhle J;
Ann Neurol; 2017 Jun; 81(6):857-870. PubMed ID: 28512753
[TBL] [Abstract][Full Text] [Related]
6. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis.
Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
J Neuroinflammation; 2018 Jul; 15(1):209. PubMed ID: 30021640
[TBL] [Abstract][Full Text] [Related]
7. The weak association between neurofilament levels at multiple sclerosis onset and cognitive performance after 9 years.
Friedova L; Motyl J; Srpova B; Oechtering J; Barro C; Vodehnalova K; Andelova M; Noskova L; Fialová L; Havrdova EK; Horakova D; Benedict RH; Kuhle J; Uher T
Mult Scler Relat Disord; 2020 Nov; 46():102534. PubMed ID: 33032055
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosis.
Koerbel K; Maiworm M; Schaller-Paule M; Schäfer JH; Jakob J; Friedauer L; Steffen F; Bittner S; Foerch C; Yalachkov Y
Mult Scler Relat Disord; 2024 Jul; 87():105644. PubMed ID: 38701697
[TBL] [Abstract][Full Text] [Related]
9. Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.
Schaller-Paule MA; Maiworm M; Schäfer JH; Friedauer L; Hattingen E; Wenger KJ; Weber F; Jakob J; Steffen F; Bittner S; Yalachkov Y; Foerch C
J Neurol; 2024 Jun; 271(6):3512-3526. PubMed ID: 38536455
[TBL] [Abstract][Full Text] [Related]
10. Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients.
Fellows K; Uher T; Browne RW; Weinstock-Guttman B; Horakova D; Posova H; Vaneckova M; Seidl Z; Krasensky J; Tyblova M; Havrdova E; Zivadinov R; Ramanathan M
J Lipid Res; 2015 Oct; 56(10):2010-8. PubMed ID: 26243484
[TBL] [Abstract][Full Text] [Related]
11. Cholesterol and neurodegeneration: longitudinal changes in serum cholesterol biomarkers are associated with new lesions and gray matter atrophy in multiple sclerosis over 5 years of follow-up.
Murali N; Browne RW; Fellows Maxwell K; Bodziak ML; Jakimovski D; Hagemeier J; Bergsland N; Weinstock-Guttman B; Zivadinov R; Ramanathan M
Eur J Neurol; 2020 Jan; 27(1):188-e4. PubMed ID: 31369181
[TBL] [Abstract][Full Text] [Related]
12. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
Siller N; Kuhle J; Muthuraman M; Barro C; Uphaus T; Groppa S; Kappos L; Zipp F; Bittner S
Mult Scler; 2019 Apr; 25(5):678-686. PubMed ID: 29542376
[TBL] [Abstract][Full Text] [Related]
13. Elevated neurofilament light chain CSF/serum ratio indicates impaired CSF outflow in idiopathic intracranial hypertension.
Engel S; Halcour J; Ellwardt E; Uphaus T; Steffen F; Zipp F; Bittner S; Luessi F
Fluids Barriers CNS; 2023 Jan; 20(1):3. PubMed ID: 36631830
[TBL] [Abstract][Full Text] [Related]
14. Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity-a cohort study.
Hegen H; Berek K; Bsteh G; Auer M; Altmann P; Di Pauli F; Grams A; Milosavljevic D; Ponleitner M; Poskaite P; Schnabl C; Wurth S; Zinganell A; Berger T; Walde J; Deisenhammer F
EBioMedicine; 2023 May; 91():104573. PubMed ID: 37086651
[TBL] [Abstract][Full Text] [Related]
15. Ratio and index of Neurofilament light chain indicate its origin in Guillain-Barré Syndrome.
Körtvelyessy P; Kuhle J; Düzel E; Vielhaber S; Schmidt C; Heinius A; Leypoldt F; Schraven B; Reinhold D; Leppert D; Goihl A
Ann Clin Transl Neurol; 2020 Nov; 7(11):2213-2220. PubMed ID: 33030817
[TBL] [Abstract][Full Text] [Related]
16. Increased cerebrospinal fluid neurofilament light chain in central nervous system inflammatory demyelinating disease.
Peng L; Bi C; Xia D; Mao L; Qian H
Mult Scler Relat Disord; 2019 May; 30():123-128. PubMed ID: 30771578
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis.
Gaetani L; Eusebi P; Mancini A; Gentili L; Borrelli A; Parnetti L; Calabresi P; Sarchielli P; Blennow K; Zetterberg H; Di Filippo M
Mult Scler Relat Disord; 2019 Oct; 35():228-232. PubMed ID: 31404762
[TBL] [Abstract][Full Text] [Related]
18. Clinical and MRI correlates of CSF neurofilament light chain levels in relapsing and progressive MS.
Damasceno A; Dias-Carneiro RPC; Moraes AS; Boldrini VO; Quintiliano RPS; da Silva VAPG; Farias AS; Brandão CO; Damasceno BP; Dos Santos LMB; Cendes F
Mult Scler Relat Disord; 2019 May; 30():149-153. PubMed ID: 30772673
[TBL] [Abstract][Full Text] [Related]
19. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis.
Fialová L; Bartos A; Svarcová J; Zimova D; Kotoucova J; Malbohan I
J Neuroimmunol; 2013 Sep; 262(1-2):113-20. PubMed ID: 23870535
[TBL] [Abstract][Full Text] [Related]
20. Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study.
Bittner S; Steffen F; Uphaus T; Muthuraman M; Fleischer V; Salmen A; Luessi F; Berthele A; Klotz L; Meuth SG; Bayas A; Paul F; Hartung HP; Linker R; Heesen C; Stangel M; Wildemann B; Then Bergh F; Tackenberg B; Kuempfel T; Weber F; Zettl UK; Ziemann U; Tumani H; Groppa S; Mühlau M; Lukas C; Hemmer B; Wiendl H; Gold R; Zipp F;
EBioMedicine; 2020 Jun; 56():102807. PubMed ID: 32460167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
